Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Campaign Highlights Value of New Drug Development
November 15, 2011
- Foreign Countries Interested in Japan’s New Promotion of Generics: IGPA Annual Conference
November 14, 2011
- Premium for Development of New Drugs Is Fiscal Neutrality System: Mr Kamoya of JPMA
November 11, 2011
- JPWA's Bessho Says Promotion of Unit-Priced Contracts by Product First and Foremost
November 11, 2011
- Trial of Premium for New Drug Development Should Continue: Dr Suzuki of JMA
November 1, 2011
- Prescription Doubts Found in 3.15% of Prescriptions, 70% of Those Were Changed: JPA Survey
October 28, 2011
- FPMAJ to Request DPJ to Make Premiums Permanent
October 27, 2011
- JPA’s Yamamoto Calls for Deliberation on TPP after Clarification
October 25, 2011
- JMA Openly Opposes TPP; JPA, JDA, JNA Express Concern
October 24, 2011
- FPMAJ Drafting GLs on Radiation Testing for Crude Drugs
October 21, 2011
- JPMA Makes Pamphlets to Promote Understanding of PC
October 20, 2011
- JPMA to Draw Up Opinion on TPP During This Month
October 20, 2011
- Toray to Join JPMA in November
October 20, 2011
- The Number of Applicants Increases 779 to 5911 for MR Exam
October 20, 2011
- Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
- JGA President Sawai Insists on Keeping 70% Rule for New Generics
October 19, 2011
- Dispensing Fees May Be Cut to Enable Hike in Medical Fees: Mr Urushibata of Chuikyo
October 18, 2011
- Vaccine Industry Must Continue to Present Proposals t oGov’t: Mr Fushimi of JAVI
October 18, 2011
- JPA Opposes TPP on Fears of Drug Safety
October 14, 2011
- Osteoporosis Foundation Survey Shows Patient Interest in Monthly BP Formulation
October 14, 2011
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…